About Myriad Genetics (NASDAQ:MYGN)
Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer. In addition, the company offers myPath Melanoma, a RNA expression test for diagnosing melanoma; myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency; and GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. Further, it provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MYGN
CUSIP62855J10
Phone801-584-3600
Debt
Debt-to-Equity Ratio0.05%
Current Ratio2.05%
Quick Ratio1.81%
Price-To-Earnings
Trailing P/E Ratio27.52
Forward P/E Ratio25.13
P/E Growth2.51
Sales & Book Value
Annual Sales$771.40 million
Price / Sales2.62
Cash Flow$1.7719 per share
Price / Cash16.31
Book Value$11.42 per share
Price / Book2.53
Profitability
EPS (Most Recent Fiscal Year)$1.05
Net Income$21.80 million
Net Margins16.67%
Return on Equity9.59%
Return on Assets6.42%
Miscellaneous
Employees2,400
Outstanding Shares69,850,000
Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions
What is Myriad Genetics' stock symbol?
Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."
How were Myriad Genetics' earnings last quarter?
Myriad Genetics (NASDAQ:MYGN) posted its quarterly earnings data on Tuesday, February, 6th. The company reported $0.31 EPS for the quarter, beating the Zacks' consensus estimate of $0.24 by $0.07. The company earned $194 million during the quarter, compared to the consensus estimate of $188.72 million. Myriad Genetics had a net margin of 16.67% and a return on equity of 9.59%. The company's quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.26 EPS. View Myriad Genetics' Earnings History.
When is Myriad Genetics' next earnings date?
What guidance has Myriad Genetics issued on next quarter's earnings?
Myriad Genetics issued an update on its FY18 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of $1.11-1.16 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.05. The company issued revenue guidance of $760-770 million, compared to the consensus revenue estimate of $770.68 million.Myriad Genetics also updated its Q3 guidance to $0.26-0.28 EPS.
What price target have analysts set for MYGN?
11 brokerages have issued 1 year price objectives for Myriad Genetics' shares. Their forecasts range from $16.00 to $45.00. On average, they anticipate Myriad Genetics' share price to reach $30.4545 in the next year. View Analyst Ratings for Myriad Genetics.
What are Wall Street analysts saying about Myriad Genetics stock?
Here are some recent quotes from research analysts about Myriad Genetics stock:
- 1. According to Zacks Investment Research, "Over the past year, Myriad Genetics has been outperforming its broader industry. Despite weaknesses in Hereditary Cancer testing revenues, Myriad Genetics exited the last reported quarter on a promising note. The raised FY18 guidance instills confidence. The company particularly observed strong growth in GeneSight testing revenues. Also Hereditary Cancer volumes growth was encouraging. Furthermore, we are upbeat about the company seeing growth in new product volumes, an expanded reimbursement for new products and an increase in international RNA kit revenues. Moreover, the company's latest receipt of manufacturing and marketing approval for its BRACAnalysis Diagnostic System in Japan buoys optimism. However, the decline in Hereditary cancer testing revenues, due to price reductions in long-term contracts, is a concern. Additionally, currency fluctuations and stiff competition are major headwinds." (4/6/2018)
- 2. Stephens analysts commented, "We initiate coverage of Nightstar Therapeutics (NITE) with a Buy rating (PT$40), on the market opportunity likely addressed by NSR- REP1 in choroideremia (CHM). Choroideremia is a rare, inherited degenerative disease of the retina that typically has onsets in childhood or early adolescence. Patients then progress to reach legal or complete blindness in their 40s or 50s. There are currently no FDA-approved disease-modifying therapies for CHM. Nightstar’s lead asset, AAV-based gene therapy, NSR-REP1, is due to enter the 140-patient pivotal phase III STAR trial in 1H18 for the treatment of CHM. With the Lancet-published phase I/II data for NSR-REP1 in CHM, and subsequent updates from the multi-center program, Nightstar has been able to show that all NSR-REP1- treated patients who received the therapeutic dose were able to maintain vision to 5 years after treatment." (1/3/2018)
Who are some of Myriad Genetics' key competitors?
Some companies that are related to Myriad Genetics include Neogen (NEOG), Immunomedics (IMMU), Quidel (QDEL), Intellia Therapeutics (NTLA), New England Nuclear (LNTH), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Quotient (QTNT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), Achieve Life Sciences (ACHV) and BG Medicine (BGMD).
Who are Myriad Genetics' key executives?
Myriad Genetics' management team includes the folowing people:
- Mr. Mark Christopher Capone, Pres, CEO & Director (Age 56)
- Mr. R. Bryan Riggsbee, CFO & Treasurer (Age 47)
- Dr. Jerry S. Lanchbury Ph.D., Chief Scientific Officer (Age 59)
- Mr. Richard M. Marsh Esq., Exec. VP, Gen. Counsel & Sec. (Age 60)
- Mr. Alexander Ford, Pres of Myriad Genetic Laboratories, Inc. (Age 51)
Has Myriad Genetics been receiving favorable news coverage?
Headlines about MYGN stock have trended somewhat positive on Monday, Accern reports. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Myriad Genetics earned a coverage optimism score of 0.10 on Accern's scale. They also gave press coverage about the company an impact score of 45.81 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Myriad Genetics?
Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myriad Genetics' stock price today?
One share of MYGN stock can currently be purchased for approximately $28.90.
How big of a company is Myriad Genetics?
Myriad Genetics has a market capitalization of $2.02 billion and generates $771.40 million in revenue each year. The company earns $21.80 million in net income (profit) each year or $1.05 on an earnings per share basis. Myriad Genetics employs 2,400 workers across the globe.
How can I contact Myriad Genetics?
Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]
MarketBeat Community Rating for Myriad Genetics (MYGN)
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe MYGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Myriad Genetics (NASDAQ:MYGN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Myriad Genetics in the last 12 months. Their average twelve-month price target is $30.4545, suggesting that the stock has a possible upside of 5.38%. The high price target for MYGN is $45.00 and the low price target for MYGN is $16.00. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 1.90 |
| Ratings Breakdown: | 2 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $30.4545 | $30.4545 | $29.40 | $24.6667 |
| Price Target Upside: | 5.38% upside | 2.89% upside | 23.87% downside | 32.44% downside |
Myriad Genetics (NASDAQ:MYGN) Consensus Price Target History
Myriad Genetics (NASDAQ:MYGN) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Myriad Genetics (NASDAQ:MYGN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Myriad Genetics (NASDAQ MYGN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.70%
Myriad Genetics (NASDAQ MYGN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/22/2018 | Richard M Marsh | VP | Sell | 37,654 | $40.25 | $1,515,573.50 | 157,648 |  |
| 1/18/2018 | Gary A King | VP | Sell | 3,120 | $38.12 | $118,934.40 | 125,088 | |
| 1/12/2018 | Richard M Marsh | VP | Sell | 13,759 | $36.25 | $498,763.75 | 136,385 | |
| 12/14/2017 | Walter Phd Gilbert | Director | Sell | 7,500 | $33.19 | $248,925.00 | | |
| 12/11/2017 | Heinrich Dreismann | Director | Sell | 6,000 | $33.50 | $201,000.00 | 33,743 | |
| 11/13/2017 | Alexander Ford | Insider | Sell | 3,031 | $31.64 | $95,900.84 | | |
| 9/1/2017 | John T Henderson | Director | Sell | 30,000 | $30.30 | $909,000.00 | 52,524 | |
| 2/23/2017 | John T Henderson | Director | Buy | 6,000 | $18.66 | $111,960.00 | 38,524 | |
| 9/12/2016 | John T Henderson | Director | Sell | 30,000 | $20.49 | $614,700.00 | 49,493 | |
| 8/19/2016 | Mark Christopher Capone | Insider | Buy | 10,000 | $21.24 | $212,400.00 | 146,026 | |
| 8/12/2016 | Ralph L Mcdade | Insider | Buy | 1,000 | $21.49 | $21,490.00 | 56,720 | |
| 6/21/2016 | Alexander Ford | Insider | Sell | 18,637 | $30.87 | $575,324.19 | 40,122 | |
| 4/6/2016 | Gary A King | VP | Sell | 15,000 | $39.03 | $585,450.00 | 95,640 | |
| 4/1/2016 | Gary A King | VP | Sell | 15,000 | $38.12 | $571,800.00 | 95,640 | |
| 12/11/2015 | Walter Phd Gilbert | Director | Sell | 5,000 | $42.23 | $211,150.00 | 12,500 | |
| 12/8/2015 | S. Louise Phanstiel | Director | Sell | 5,000 | $44.00 | $220,000.00 | 8,500 | |
| 11/5/2015 | Heinrich Dreismann | Director | Sell | 60,000 | $44.44 | $2,666,400.00 | 10,000 | |
| 11/4/2015 | Richard M. Marsh | VP | Sell | 35,000 | $44.50 | $1,557,500.00 | 68,384 | |
| 10/28/2015 | Gary A. King | VP | Sell | 10,000 | $42.82 | $428,200.00 | 80,573 | |
| 10/28/2015 | Jerry S. Lanchbury | insider | Sell | 50,962 | $41.86 | $2,133,269.32 | 70,737 | |
| 10/27/2015 | Jerry S. Lanchbury | insider | Sell | 24,767 | $41.80 | $1,035,260.60 | 70,737 | |
| 9/17/2015 | Jerry S. Lanchbury | insider | Sell | 60,270 | $39.89 | $2,404,170.30 | 70,737 | |
| 9/16/2015 | Richard M. Marsh | VP | Sell | 35,000 | $41.25 | $1,443,750.00 | 67,543 | |
| 9/14/2015 | Gary A. King | VP | Sell | 14,562 | $39.41 | $573,888.42 | 51,473 | |
| 9/3/2015 | Gary A. King | VP | Sell | 25,438 | $39.41 | $1,002,511.58 | 51,473 | |
| 9/2/2015 | Gary A. King | VP | Sell | 15,000 | $38.23 | $573,450.00 | 51,473 | |
| 8/28/2015 | Gary A. King | VP | Sell | 30,000 | $35.73 | $1,071,900.00 | 51,473 | |
| 11/3/2014 | Gary A King | VP | Sell | 6,568 | $39.95 | $262,391.60 | | |
| 9/30/2014 | James S Evans | CFO | Sell | 21,850 | $38.99 | $851,931.50 | | |
| 9/24/2014 | James S Evans | CFO | Sell | 8,790 | $37.98 | $333,844.20 | | |
| 9/23/2014 | James S Evans | CFO | Sell | 110,463 | $37.89 | $4,185,443.07 | | |
| 7/14/2014 | Peter D Meldrum | Insider | Sell | 24,000 | $39.50 | $948,000.00 | | |
| 6/5/2014 | John T Henderson | Director | Sell | 5,000 | $35.70 | $178,500.00 | | |
| 5/9/2014 | Ronald Rogers | VP | Sell | 12,500 | $36.01 | $450,125.00 | | |
| 4/30/2014 | Richard Marsh | VP | Sell | 30,000 | $41.80 | $1,254,000.00 | 18,285 | |
| 4/23/2014 | Richard Marsh | VP | Sell | 31,516 | $39.80 | $1,254,336.80 | 18,285 | |
| 4/16/2014 | Richard Marsh | VP | Sell | 28,484 | $39.80 | $1,133,663.20 | 18,285 | |
| 4/7/2014 | Jayne Hart | VP | Sell | 79,000 | $40.90 | $3,231,100.00 | 930 | |
| 4/2/2014 | James Evans | CFO | Sell | 80,000 | $40.00 | $3,200,000.00 | 47,609 | |
| 4/2/2014 | Peter Meldrum | Insider | Sell | 55,000 | $39.57 | $2,176,350.00 | 15,084 | |
| 3/19/2014 | Peter Meldrum | Insider | Sell | 55,000 | $37.00 | $2,035,000.00 | 26,084 | |
| 3/17/2014 | Peter Meldrum | Insider | Sell | 55,000 | $35.15 | $1,933,250.00 | 26,084 | |
| 3/12/2014 | Richard Marsh | VP | Sell | 50,000 | $34.37 | $1,718,500.00 | 17,165 | |
| 2/26/2014 | Walter Phd Gilbert | Director | Sell | 30,000 | $37.58 | $1,127,400.00 | | |
| 2/25/2014 | Mark Christopher Capone | Insider | Sell | 95,250 | $37.83 | $3,603,307.50 | 48,268 | |
| 2/24/2014 | Gary King | VP | Sell | 20,000 | $38.00 | $760,000.00 | 2,949 | |
| 2/20/2014 | James Evans | CFO | Sell | 30,000 | $36.01 | $1,080,300.00 | 47,609 | |
| 2/20/2014 | Robert Gardner Harrison | Insider | Sell | 17,554 | $36.22 | $635,805.88 | 324 | |
| 2/19/2014 | Richard Marsh | VP | Sell | 34,676 | $34.71 | $1,203,603.96 | 17,165 | |
| 2/19/2014 | Walter Phd Gilbert | Director | Sell | 60,000 | $34.48 | $2,068,800.00 | | |
| 2/18/2014 | Gary King | VP | Sell | 25,000 | $34.74 | $868,500.00 | 2,949 | |
| 2/18/2014 | Heinrich Dreismann | Director | Sell | 30,000 | $35.00 | $1,050,000.00 | | |
| 2/14/2014 | Richard Marsh | VP | Sell | 20,960 | $31.50 | $660,240.00 | 17,165 | |
| 2/12/2014 | Robert Gardner Harrison | Insider | Sell | 13,707 | $30.74 | $421,353.18 | 324 | |
| 2/10/2014 | Mark Christopher Capone | Insider | Sell | 87,500 | $32.07 | $2,806,125.00 | 48,268 | |
| 2/7/2014 | James Evans | CFO | Sell | 35,000 | $33.04 | $1,156,400.00 | 47,609 | |
| 2/5/2014 | Peter Meldrum | Insider | Sell | 123,940 | $31.10 | $3,854,534.00 | 55,656 | |
| 11/8/2013 | James Evans | CFO | Sell | 8,072 | $26.50 | $213,908.00 | 47,177 | |
| 11/8/2013 | Peter Meldrum | Insider | Sell | 31,784 | $26.50 | $842,276.00 | 55,656 | |
| 6/13/2013 | Robert Gardner Harrison | Insider | Sell | 31,498 | $36.17 | $1,139,282.66 | | |
| 5/16/2013 | Mark Christopher Capone | Insider | Sell | 79,999 | $33.23 | $2,658,366.77 | | |
| 5/14/2013 | Peter D Meldrum | Insider | Sell | 15,000 | $34.00 | $510,000.00 | | |
| 5/10/2013 | Heinrich Dreismann | Director | Sell | 30,000 | $31.16 | $934,800.00 | | |
| 5/10/2013 | Peter D Meldrum | Insider | Sell | 75,960 | $31.99 | $2,429,960.40 | | |
| 5/10/2013 | Richard M Marsh | VP | Sell | 48,192 | $33.00 | $1,590,336.00 | | |
| 10/4/2012 | Jerry S Lanchbury | Insider | Sell | 3,900 | $28.50 | $111,150.00 | | |
| 10/3/2012 | Jerry S Lanchbury | Insider | Sell | 3,000 | $28.50 | $85,500.00 | | |
| 9/14/2012 | Peter D Meldrum | Insider | Sell | 20,000 | $27.60 | $552,000.00 | | |
| 9/13/2012 | James S Evans | CFO | Sell | 5,494 | $27.10 | $148,887.40 | | |
(Data available from 1/1/2013 forward)
Myriad Genetics (NASDAQ MYGN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Myriad Genetics (MYGN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 22 at 5:48 AM |
 | Pomerantz Law Firm Announces the Filing of a Class Action against Myriad Genetics, Inc. and Certain Officers – MYGN
feeds.benzinga.com - April 20 at 10:09 PM |
 | Here's Why You Should Invest in Integer Holdings Right Now
finance.yahoo.com - April 20 at 3:28 PM |
| Zacks: Brokerages Expect Myriad Genetics (MYGN) Will Post Quarterly Sales of $187.99 Million
www.americanbankingnews.com - April 20 at 2:48 AM |
| Myriad Genetics Is Poised for a Rebound on the Charts
finance.yahoo.com - April 19 at 3:27 PM |
| Myriad Announces Launch of "Go Green" Sustainability Initiative In Support of Earth Day
finance.yahoo.com - April 19 at 9:37 AM |
| $0.27 Earnings Per Share Expected for Myriad Genetics (MYGN) This Quarter
www.americanbankingnews.com - April 18 at 3:08 PM |
| Intuitive Surgical (ISRG) Beats on Q1 Earnings & Revenues
finance.yahoo.com - April 18 at 10:48 AM |
| Myriad Genetics (MYGN) Downgraded to Buy at BidaskClub
www.americanbankingnews.com - April 17 at 1:54 PM |
| Myriad Genetics (MYGN) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 13 at 4:23 PM |
| Barclays Cuts Myriad Genetics (MYGN) Price Target to $26.00
www.americanbankingnews.com - April 11 at 7:53 PM |
| Myriad Genetics (MYGN) Rating Increased to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - April 6 at 10:22 PM |
 | Global Genetic Testing Market 2018-2022 - Key Vendors are Abbott, bioMrieux, Bio-Rad Laboratories, F. Hoffmann-La Roche, Myriad Genetics, QIAGEN & Quest Diagnostics
www.prnewswire.com - April 6 at 3:48 PM |
| Myriad Genetics (MYGN) Lifted to "Strong-Buy" at Zacks Investment Research
www.americanbankingnews.com - April 6 at 11:00 AM |
| Is Myriad Genetics, Inc. a Buy?
finance.yahoo.com - April 5 at 9:30 AM |
| Myriad Genetics' BRACAnalysis Test Platform Gets PMA in Japan
finance.yahoo.com - April 4 at 4:41 PM |
| Myriad Genetics' BRACAnalysis Test Platform Gets PMA in Japan
finance.yahoo.com - April 4 at 4:41 PM |
| Wired News – Myriad Genetics Receives Japanese Regulatory Approval for BRACAnalysis(R) Diagnostic System
finance.yahoo.com - April 4 at 10:26 AM |
| ValuEngine Upgrades Myriad Genetics (MYGN) to Buy
www.americanbankingnews.com - April 3 at 11:38 AM |
| $187.82 Million in Sales Expected for Myriad Genetics (MYGN) This Quarter
www.americanbankingnews.com - April 3 at 3:23 AM |
 | Myriad Genetics (MYGN) Announces Pre-Market Approval for its BRACAnalysis Diagnostic System in Japan
www.streetinsider.com - April 2 at 3:28 PM |
 | Myriad Genetics BRACAnalysis test OK'd in Japan as companion diagnostic with Lynparza
seekingalpha.com - April 2 at 9:46 AM |
| Myriad Genetics (MYGN) Expected to Announce Earnings of $0.27 Per Share
www.americanbankingnews.com - April 1 at 1:14 PM |
| Myriad Genetics (MYGN) Price Target Raised to $30.00
www.americanbankingnews.com - April 1 at 9:47 AM |
| Myriad Genetics (MYGN) Price Target Raised to $26.00 at Morgan Stanley
www.americanbankingnews.com - April 1 at 9:46 AM |
| Myriad Genetics (MYGN) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 28 at 5:52 AM |
| Myriad Genetics (MYGN) Given a $41.00 Price Target at BTIG Research
www.americanbankingnews.com - March 27 at 8:34 PM |
| Myriad Genetics (MYGN) Downgraded by BidaskClub
www.americanbankingnews.com - March 24 at 8:23 PM |
 | Health Care Sector Update for 03/21/2018: MYGN,AKTX,FENC,FRX.TO,VIVO - Nasdaq
www.nasdaq.com - March 22 at 3:31 PM |
| Myriad Genetics (MYGN) Stock Rating Upgraded by Morgan Stanley
www.americanbankingnews.com - March 21 at 6:40 PM |
 | Glancy Prongay & Murray LLP Continues Investigation on Behalf of Myriad Genetics, Inc. Investors (MYGN) - Business Wire (press release)
www.businesswire.com - March 21 at 11:42 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors Myriad Genetics, Inc.
finance.yahoo.com - March 20 at 3:37 PM |
| MYRIAD GENETICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Myriad Genetics, Inc. To Contact The Firm
www.prnewswire.com - March 19 at 8:19 PM |
| MYGN INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Myriad Genetics, Inc ... - Business Wire (press release)
www.businesswire.com - March 19 at 3:31 PM |
| Bragar Eagel & Squire, PC is Investigating Myriad Genetics, Inc. (MYGN) on Behalf of Stockholders and Encourages ... - Business Wire (press release)
www.businesswire.com - March 19 at 3:31 PM |
| MYGN INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Myriad Genetics, Inc. Investors
finance.yahoo.com - March 19 at 3:31 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myriad Genetics, Inc ... - PR Newswire (press release)
www.prnewswire.com - March 17 at 8:18 AM |
| INVESTOR ALERT: Kirby McInerney LLP Announces Investigation on Behalf of Myriad Genetics, Inc. (MYGN) Investors - Business Wire (press release)
www.businesswire.com - March 17 at 8:18 AM |
| MYGN INVESTOR ALERT: Law Offices of Howard G. Smith ... - Business Wire (press release)
www.businesswire.com - March 17 at 8:18 AM |
| Analysts Expect Myriad Genetics, Inc. (MYGN) Will Announce Quarterly Sales of $187.82 Million
www.americanbankingnews.com - March 17 at 5:52 AM |
| Glancy Prongay & Murray LLP Announces Investigation on Behalf of Myriad Genetics, Inc. Investors (MYGN) - Business Wire (press release)
www.businesswire.com - March 16 at 3:25 PM |
| Glancy Prongay & Murray LLP Announces Investigation on Behalf of Myriad Genetics, Inc. Investors (MYGN)
finance.yahoo.com - March 16 at 3:25 PM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Myriad Genetics, Inc. (MYGN) - PR Newswire (press release)
www.prnewswire.com - March 15 at 3:31 PM |
| Scott+Scott Attorneys at Law LLP Announces Investigation into Myriad Genetics, Inc. (MYGN) - PR Newswire (press release)
www.prnewswire.com - March 15 at 3:31 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myriad Genetics, Inc. - MYGN
finance.yahoo.com - March 15 at 3:31 PM |
| Scott+Scott Attorneys at Law LLP Announces Investigation into Myriad Genetics, Inc. (MYGN)
finance.yahoo.com - March 15 at 3:31 PM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Myriad Genetics, Inc. (MYGN)
finance.yahoo.com - March 15 at 3:31 PM |
| $0.27 Earnings Per Share Expected for Myriad Genetics, Inc. (MYGN) This Quarter
www.americanbankingnews.com - March 15 at 11:25 AM |
 | Here's Why Myriad Genetics Stock Fell as Much as 13.7% Today ... - Motley Fool
www.fool.com - March 15 at 8:19 AM |
| Myriad Genetics (MYGN) Downgraded by ValuEngine
www.americanbankingnews.com - March 13 at 10:20 PM |
Myriad Genetics (NASDAQ:MYGN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Myriad Genetics (NASDAQ:MYGN) Income Statement, Balance Sheet and Cash Flow Statement
Myriad Genetics (NASDAQ MYGN) Stock Chart for Monday, April, 23, 2018
Loading chart…
